GRPR and prostate carcinoma: However, a phase I escalation study conducted in patients with metastatic castration-resistant prostate cancer was discontinued due to the severe adverse effects induced by GRPR activation after injection of therapeutic doses of [177Lu]Lu-AMBA [27].